Oncology · Liver CancerTrial Updateclinicalmid-term

Study on 188Re-SSS Lipiodol SIRT for Non-Operable Liver Cancer Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:31:40 AM

Assessment confidence: 80% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The initiation of this trial on 188Re-SSS lipiodol SIRT for non-operable liver cancer is significant as it may lead to new treatment options and shift current therapeutic paradigms. Monitoring its outcomes is crucial for understanding potential impacts on market dynamics and treatment guidelines. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 7 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this trial as it may influence treatment guidelines and competitive positioning in liver cancer therapies. The strongest clinical anchor is Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) (ClinicalTrials.gov), sub-indication match (liver cancer). If successful, this treatment could capture market share from existing therapies, influencing revenue streams for companies involved in liver cancer treatments.

Competitive Pressure

The most relevant competitive pressure comes from This trial could provide insights into a novel treatment approach for non-operable HCC, potentially impacting existing therapies and market dynamics..

Regulatory Outlook

Regulatory risk is concentrated around The trial results could inform future regulatory submissions and treatment guidelines, affecting compliance and approval processes for liver cancer therapies..

Key Risks

Elevated medium regulatory exposure for non-operable hepatocellular carcinoma (HCC) could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If successful, this treatment could capture market share from existing therapies, influencing revenue streams for companies involved in liver cancer treatments.
Portfolio teams should monitor the outcomes of this trial as it may influence treatment guidelines and competitive positioning in liver cancer therapies.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and final efficacy data from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)
ClinicalTrials.govhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
ClinicalTrials.govhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer
ClinicalTrials.govmedium relevance
Sub-indication match (liver cancer)
FDA document
View source
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Panc
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

No evidence in this category.

Patients with Favorable Prognosis among Those Selected for Liver Resection for Intermediate-Stage Hepatocellular Carcinoma.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
MAGED4 promotes hepatocellular carcinoma progression via activation of JAK2/STAT3 pathway by stabilizing TRIM21.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.
PubMedhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Compliance with preoperative antibiotic prophylaxis in cesarean delivery and its impact on surgical site infections: A national retrospective study of Jordan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

non-operable hepatocellular carcinoma (HCC)
existing liver cancer therapies

Commercial impact

medium

If successful, this treatment could capture market share from existing therapies, influencing revenue streams for companies involved in liver cancer treatments.

Regulatory impact